Shen Lian Biomedical(SH:688098) Xin Lang Cai Jing·2025-10-31 05:31Core Viewpoint - Shenyuan Biological is a leading enterprise in the field of veterinary synthetic peptide vaccines in China, with a focus on research, production, and sales of veterinary biological products [1] Group 1: Business Performance - In Q3 2025, Shenyuan Biological reported revenue of 238 million yuan, ranking 10th in the industry, significantly lower than the top company, Zhongmu Co., which had 4.442 billion yuan, and the second, Ruipu Biological, with 2.544 billion yuan [2] - The net profit for the same period was -3.0229 million yuan, placing the company 12th in the industry, far behind Ruipu Biological's 391 million yuan and KQ Biological's 337 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenyuan Biological's debt-to-asset ratio was 8.94%, an increase from 6.72% year-on-year, but still below the industry average of 28.36% [3] - The gross profit margin for Q3 2025 was 59.49%, down from 61.12% year-on-year, yet higher than the industry average of 40.13% [3] Group 3: Executive Compensation - The chairman, Nie Dongsheng, received a salary of 1.1286 million yuan in 2024, a decrease of 49,000 yuan from 2023 [4] - The general manager, Zhang Zhen, had a salary of 990,000 yuan in 2024, an increase of 46,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 30.87% to 12,400, while the average number of circulating A-shares held per account decreased by 23.59% to 33,100 [5]